Key stats
About LEGAL & GENERAL UCITS ETF PLC - L&G PHARMA BREAKTHROUGH UCITS ETF
Home page
Inception date
Jan 23, 2018
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BF0H7608
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.96%
Health Technology91.39%
Process Industries5.66%
Finance2.91%
Bonds, Cash & Other0.04%
Cash0.04%
Stock breakdown by region
North America54.75%
Europe24.12%
Asia21.12%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
ETLI invests in stocks. The fund's major sectors are Health Technology, with 91.39% stocks, and Process Industries, with 5.66% of the basket. The assets are mostly located in the North America region.
ETLI top holdings are InnoCare Pharma Ltd. and Zevra Therapeutics, Inc., occupying 5.12% and 4.03% of the portfolio correspondingly.
No, ETLI doesn't pay dividends to its holders.
ETLI shares are issued by Legal & General Group Plc under the brand L&G. The ETF was launched on Jan 23, 2018, and its management style is Passive.
ETLI expense ratio is 0.49% meaning you'd have to pay 0.49% of your investment to help manage the fund.
ETLI follows the Solactive Pharma Breakthrough Value Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
ETLI invests in stocks.